Awiqli for LADA: Not Recommended as First-Line Therapy
Awiqli (insulin icodec) is FDA-approved only for type 2 diabetes and should not be used in LADA patients, who have an autoimmune form of diabetes more similar to type 1 diabetes and require different insulin management strategies. 1
Why Awiqli is Inappropriate for LADA
FDA Indication Limitation
- Awiqli is specifically indicated "as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus" only 1
- The FDA label explicitly states to consider insulin as first injectable "when a diagnosis of type 1 diabetes is a possibility" - which applies directly to LADA 2
- LADA (Latent Autoimmune Diabetes in Adults) is an autoimmune condition representing slow-onset type 1 diabetes in adults, not type 2 diabetes
Clinical Concerns with Long-Acting Weekly Insulin in LADA
- Awiqli has an extremely long half-life requiring weekly dosing 1
- The FDA label warns that "adjustment of dose is not advised during acute illness" due to this long half-life 1
- LADA patients have progressive beta-cell destruction and unpredictable insulin requirements as their disease evolves
- The inability to rapidly adjust dosing in response to changing insulin needs makes weekly insulin dangerous in autoimmune diabetes
Appropriate Insulin Management for LADA
Recommended Approach
Start with daily basal insulin analogs (insulin glargine, detemir, or degludec) combined with rapid-acting insulin as needed 2
Starting Dose for Daily Basal Insulin
- 10 units per day OR 0.1-0.2 units/kg per day 2
- Set fasting plasma glucose goal (typically <130 mg/dL initially, individualized based on patient factors)
Titration Algorithm
- Increase by 2 units every 3 days to reach fasting glucose goal without hypoglycemia 2
- For hypoglycemia: determine cause; if no clear reason, lower dose by 10-20% 2
- Assess adequacy at every visit (every 3-6 months) 2
Key Monitoring Points
- LADA patients often require earlier addition of prandial insulin than typical type 2 diabetes patients due to progressive beta-cell failure
- Watch for signs of inadequate basal insulin: elevated bedtime-to-morning glucose differential, postprandial excursions, or increasing glucose variability 2
- Consider C-peptide and GAD antibody testing to confirm LADA diagnosis and guide insulin intensification timing
Critical Pitfall to Avoid
Do not treat LADA as type 2 diabetes. The autoimmune destruction of beta cells means these patients will eventually require full basal-bolus insulin therapy similar to type 1 diabetes. Using a weekly insulin like Awiqli could result in:
- Inability to rapidly adjust for declining endogenous insulin production
- Prolonged hyperglycemia or hypoglycemia due to inflexible dosing
- Increased risk of diabetic ketoacidosis if insulin needs suddenly increase
The 2025 ADA guidelines emphasize considering insulin as first injectable therapy "when a diagnosis of type 1 diabetes is a possibility" 2, which directly applies to LADA patients who represent a form of autoimmune diabetes requiring type 1 diabetes management principles.